Novan, Inc. (NOVN)
Stock Price:
$0.501 USD
-0.010 (-1.86%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $0.500 -0.001 (-0.10%) Oct 27, 7:58 PM
Key Info
| Market Cap |
68.80M |
| Revenue (ttm) |
5.23M |
| Net Income (ttm) |
-19.51M |
| Shares Out |
137.47M |
| EPS (ttm) |
-0.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$0.501 |
| Previous Close |
$0.510 |
| Change ($) |
-0.010 |
| Change (%) |
-1.86% |
| Day's Open |
0.519 |
| Day's Range |
0.490 - 0.520 |
| Day's Volume |
2,610,812 |
| 52-Week Range |
0.215 - 3.720 |
More Stats
| Market Cap |
68.80M |
| Enterprise Value |
39.72M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
137.47M |
| Float |
127.40M |
| EPS (basic) |
-0.47 |
| EPS (diluted) |
-0.70 |
| FCF / Share |
-0.42 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.56M |
| Short Ratio |
0.54 |
| Short % of Float |
4.36% |
| Beta |
-0.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
13.16 |
| PB Ratio |
n/a |
| Revenue |
5.23M |
| Operating Income |
-29.87M |
| Net Income |
-19.51M |
| Free Cash Flow |
-33.47M |
| Net Cash |
29.09M |
| Net Cash / Share |
0.21 |
| Gross Margin |
-96.00% |
| Operating Margin |
-571.26% |
| Profit Margin |
-373.10% |
| FCF Margin |
-640.10% |
| ROA |
-36.36% |
| ROE |
n/a |
| ROIC |
-282.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.00*
(499.40% upside)
Low
1.50
Current: $0.501
High
4.50
Target: 3.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 4.90 | 5.99 | 2.65 | - | - | 0.11 |
| Revenue Growth | -18.28% | 126.42% | - | - | - | - |
| Gross Profit | 4.90 | 5.99 | 2.65 | - | - | 0.11 |
| Operating Income | -30.69 | -28.56 | -35.68 | -59.83 | -25.83 | -11.83 |
| Net Income | -30.38 | -29.24 | -36.62 | -59.70 | -28.06 | -11.39 |
| Shares Outstanding | 26.25 | 25.80 | 15.98 | 5.99 | 2.27 | 2.20 |
| Earnings Per Share | -1.16 | -1.13 | -2.29 | -9.97 | -12.37 | -5.17 |
| Operating Cash Flow | -19.88 | -28.63 | -29.86 | -49.17 | -22.19 | -8.60 |
| Capital Expenditures | -0.42 | -1.06 | -2.14 | -6.22 | -1.21 | -0.77 |
| Free Cash Flow | -20.30 | -29.68 | -32.00 | -55.39 | -23.40 | -9.38 |
| Cash & Equivalents | 14.25 | 8.73 | 3.06 | 35.15 | 46.23 | 7.42 |
| Total Debt | 6.26 | 8.02 | 8.03 | 8.04 | 0.01 | 0.02 |
| Net Cash / Debt | 7.99 | 0.71 | -4.97 | 27.11 | 46.22 | 7.40 |
| Assets | 29.10 | 26.36 | 21.13 | 52.47 | 49.82 | 9.93 |
| Liabilities | 51.38 | 19.92 | 22.85 | 21.41 | 5.10 | 1.78 |
| Book Value | -22.28 | 6.44 | -1.72 | 31.07 | -60.08 | -29.55 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Novan, Inc. |
| Country |
United States |
| Employees |
25 |
| CEO |
Paula Brown Stafford |
Stock Information
| Ticker Symbol |
NOVN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NOVN |
| IPO Date |
September 21, 2016 |
Description
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Company; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.